医脉通|逆转动脉粥样硬化?掌握两大武器( 三 )


[8] Mach F, Baigent C, Catapano A L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)[J]. European heart journal, 2019, 41(1): 111-188.
[9] Chhatriwalla A K, Nicholls S J, Wang T H, et al. Low levels of low-density lipoprotein cholesterol and blood pressure and progression of coronary atherosclerosis[J]. Journal of the American College of Cardiology, 2009, 53(13): 1110-1115.
[10] Hirohata A, Yamamoto K, Miyoshi T, et al. Impact of olmesartan on progression of coronary atherosclerosis: a serial volumetric intravascular ultrasound analysis from the OLIVUS (impact of olmesarten on progression of coronary atherosclerosis: evaluation by intravascular ultrasound) trial[J]. Journal of the American College of Cardiology, 2010, 55(10): 976-982.
[11] Nissen S E, Nicholls S J, Wolski K, et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial[J]. Jama, 2008, 299(13): 1561-1573.
【医脉通|逆转动脉粥样硬化?掌握两大武器】本文为***作者原创 , 未经授权不得转载


推荐阅读